Atripla

Type: Product
Name: Atripla
First reported Oct 15 2014 - Updated Oct 15 2014 - 1 reports

Bristol Myers Squibb : Statement on Sustiva efavirenz in the U.S.

By a News Reporter-Staff News Editor at AIDS Weekly -- Bristol-Myers Squibb Company (NYSE:BMY) has successfully resolved all outstanding U.S. patent litigation relating to efavirenz, an active ingredient contained in our Sustiva (efavirenz) and Atripla ... [Published 4 Traders - Oct 15 2014]
First reported Oct 15 2014 - Updated Oct 15 2014 - 1 reports

IDWeek 2014: Complera Matches Atripla for Women Starting HIV Treatment

Details Category: Approved HIV Drugs Published on Wednesday, 15 October 2014 00:00 Written by Liz HighleymanThe Complera (rilpivirine/tenofovir/emtricitabine) single-tablet regimen worked as well as Atripla (efavirenz/tenofovir/emtricitabine) for ... [Published HIV and Hepatitis.com - Oct 15 2014]
First reported Oct 13 2014 - Updated Oct 13 2014 - 1 reports

A Global Product and Pipeline Analysis of Antiretroviral Drug Development for the Treatment of HIV/AIDS

NEW YORKKey FindingsHuman Immunodeficiency Virus (HIV) AntiretroviralsThe 2006 launch of Atripla, the first single-tablet regimen (STR) for the treatment of HIV infection, marked an important advancement in antiretroviral therapy (ART), significantly ... [Published Bio-Medicine - Oct 13 2014]
First reported Oct 10 2014 - Updated Oct 11 2014 - 1 reports

Gilead's October Events Should Drive The Stock To The Next Leg Of Consolidation

By BMD Asset Management and Research :Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes medicines for the treatment of life-threatening diseases worldwide. The company's main products include Sovaldi, Atripla, ... [Published BioPortfolio - Oct 10 2014]
First reported Oct 09 2014 - Updated Oct 10 2014 - 1 reports

Gilead Sciences, Inc. (GILD) Bulls Roll the Dice On a New Record High

Stocks quoted in this article:Gilead Sciences, Inc. (NASDAQ:GILD) is succumbing to today's broad-market bloodbath , and was last seen off 2.6% to $106.01. Traders are paying no mind, however, and are scooping up calls at 1.2 times the expected intraday ... [Published Schaeffers Research - Oct 09 2014]
First reported Oct 09 2014 - Updated Oct 09 2014 - 1 reports

Exchange enrollees have high need for expensive drugs

By Bob Herman6:45 pm, Oct. 8 |Early analysis suggests many people who bought health plans on exchanges had multiple medical problems and frequently sought out costly drugs to combat those complex conditions. New data shows that they filled 59% more prescriptions ... [Published Modern Healthcare - Oct 09 2014]
First reported Oct 08 2014 - Updated Oct 08 2014 - 4 reports

Bristol-Myers resolves Sustiva patent litigation in USA

US pharma major Bristol-Myers Squibb (NYSE: BMY) has successfully resolved all outstanding US patent litigation relating to efavirenz, an active ingredient contained in HIV/AIDS drugs Sustiva (efavirenz) and Atripla (efavirenz/emtricitabine/tenofovir ... [Published Pharma Letter - Oct 08 2014]
First reported Oct 08 2014 - Updated Oct 08 2014 - 1 reports

Recent developments keep Gilead ahead of the pack in HIV treatment market, says GlobalData Analyst

Gilead’s announcement of positive Phase III results for its investigational single-tablet regimen (STR), elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (TAF), caps a series of developments bolstering the company’s position as HIV ... [Published European Pharmaceutical Review - Oct 08 2014]
First reported Oct 08 2014 - Updated Oct 08 2014 - 1 reports

Five things for pharma marketers to know: Wednesday, October 8

Share this article:Web exclusiveConsulting and tech firm Cognizant is acquiring Pennsylvania-based healthcare communications agency Cadient Group in a deal that will move the agency's more than 100 digital specialists from to Cognizant's Healthcare and ... [Published Medical Marketing And Media - Oct 08 2014]
First reported Sep 28 2014 - Updated Sep 28 2014 - 1 reports

ViiV’s Triumeq to End Gilead’s Monopoly in Anti-HIV, Says GlobalData

The recent approval of ViiV Healthcare’s once-daily, single-tablet anti-HIV regimen, Triumeq, by the US Food and Drug Administration (FDA) and the European Commission (EC) will mean that the market monopoly currently held by Gilead Sciences will soon ... [Published PharmaAsia - Sep 28 2014]
First reported Sep 25 2014 - Updated Sep 26 2014 - 1 reports

This Switch Could Make Gilead Sciences, Inc. Stock Billions

What's in a name? For Gilead Sciences ( NASDAQ: GILD     ) , a few billion dollars.Tenofovir alafenamide and tenofovir disoproxil fumarate may sound similar enough (and also a mouthful), but tenofovir alafenamide, commonly referred to as TAF, is worth ... [Published Motley Fool Discussion Boards - Sep 25 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

My Four-Year Journey With Atripla

This article was cross-posted from " A Girl Like Me ," a program of The Well Project .I want to start this blog by saying this: if you are taking Atripla , remember that everyone's body is different ... I am talking about my own experience and this is ... [Published The Body - Sep 26 2014]

Quotes

"My main concern is that health education should start in schools," Stone said. "It's required by law, but they're not teaching it, and there's no consequence. We were always more welcome to speak in Muhlenberg and Ohio (county's schools)."
...in terms of virologic suppression at both Week 48 and Week 96 with low rates of virologic failure in both arms," the researchers concluded. "There was no difference in rates of virological suppression between genders."
...world databases, HIV patients with depression and psychiatric conditions were less likely to be prescribed efavirenz," the researchers concluded. "Despite [propensity score]-adjustment, we did not find conclusive evidence of an increased risk of suicidality or suicide attempt among patients initiating an efavirenz-containing regimen."

More Content

All (51) | News (45) | Reports (0) | Blogs (6) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
End Of The Year Events To Drive Some Of October... [Published Seeking Alpha - 45 mins ago]
'I didn't always think I'd live this long': Sto... [Published Insurance News Net - Oct 19 2014]
A Harvoni Vs. Olysio Price War Will Be Nonexist... [Published Seeking Alpha - Oct 17 2014]
Bristol Myers Squibb : Statement on Sustiva efa... [Published 4 Traders - Oct 15 2014]
IDWeek 2014: Complera Matches Atripla for Women... [Published HIV and Hepatitis.com - Oct 15 2014]
IDWeek 2014: Efavirenz Not Linked to Suicide in... [Published HIV and Hepatitis.com - Oct 15 2014]
A Global Product and Pipeline Analysis of Antir... [Published Bio-Medicine - Oct 13 2014]
A Global Product and Pipeline Analysis of Antir... [Published Scottrade - Oct 13 2014]
Motley Fool for Oct. 11, 2014 [Published St Augustine Herald - Oct 11 2014]
Company Update: Gilead Sciences Inc (NASDAQ:GIL... [Published Jutia Group - Oct 10 2014]
10 things your health insurance won't tell you -2- [Published Morningstar.com - Oct 10 2014]
Gilead's October Events Should Drive The Stock ... [Published BioPortfolio - Oct 10 2014]
Gilead's October Events Should Drive The Stock ... [Published Seeking Alpha - Oct 10 2014]
Gilead Sciences, Inc. (GILD) Bulls Roll the Dic... [Published Schaeffers Research - Oct 09 2014]
Exchange enrollees have high need for expensive... [Published Modern Healthcare - Oct 09 2014]
Bristol-Myers resolves Sustiva patent litigatio... [Published Pharma Letter - Oct 08 2014]
Recent developments keep Gilead ahead of the pa... [Published European Pharmaceutical Review - Oct 08 2014]
Five things for pharma marketers to know: Wedne... [Published Medical Marketing And Media - Oct 08 2014]
Bristol-Myers Says Successfully Resolved All U.... [Published RTTNews.com - Oct 08 2014]
Bristol-Myers Squibb Statement on Sustiva (efav... [Published RCL Advisors - Oct 08 2014]
Bristol-Myers Squibb Statement on Sustiva (efav... [Published Business Wire Health News - Oct 08 2014]
HIV-AIDS Testing Market - Global Industry Analy... [Published SBWire - Oct 06 2014]
Gilead Sciences' Other Important New Drug [Published Motley Fool Discussion Boards - Oct 05 2014]
Gilead Sciences, Inc. Got 2 Drugs Approved, and... [Published Motley Fool Discussion Boards - Oct 04 2014]
The Importance Of TAF To Gilead [Published Seeking Alpha - Oct 03 2014]
Gay blogger Andrew Sullivan: Almost every man h... [Published Pink News - Oct 01 2014]
Is The HIV Divide Now Over? [Published Atlantic Monthly - Sep 30 2014]
Is The HIV Divide Now Over? [Published The Daily Dish | By Andrew Sullivan - Sep 30 2014]
FDA approves new HIV drug booster cobicistat as... [Published Project Inform - Sep 29 2014]
ViiV’s Triumeq to End Gilead’s Monopoly in Anti... [Published PharmaAsia - Sep 28 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Bristol-Myers Squibb Statement on Sustiva (efav... [Published Business Wire Health News - Oct 08 2014]
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) has successfully resolved all outstanding U.S. patent litigation relating to efavirenz, an active ingredient contained in our Sustiva (efavirenz) and Atripla (efavirenz/emtricitabine/tenofovir ...
Is The HIV Divide Now Over? [Published The Daily Dish | By Andrew Sullivan - Sep 30 2014]
What are your options today as a gay man with a sex life in America? You live in a community where a deadly virus has killed hundreds of thousands and is still resilient in the gay male world as a whole. It has no external or visible symptoms most of ...
HIV Infection Rates On the Rise in Austin [Published Burnt Orange Report - Sep 12 2014]
In the 1980's during the AIDS epidemic, the gay community in Austin lost many members to the disease. Now, infection rates in Austin are again on the rise. Ashley Womble at Austin Monthly looked into this increase, and found that the HIV-positive ...
HIV and Medicare, Even if you Aren't HIV Positive [Published InsureBlog - Aug 14 2014]
Should you have to pay for treatment for a condition you don't have? How about Medicare? Would you expect Medicare to pay for treatment for a Medicare beneficiary if they are not sick? Two years ago, the prescription drug program, known as Part D, ...
Why Gilead Sciences Is a Must-Own Stock [Published Wall St. Cheat Sheet - Jun 30 2014]
Source: Thinkstock Gilead Sciences Inc . ( NASDAQ:GILD ) is one of my top choices for any stocks moving forward through 2014 into 2015. This company is a behemoth of a biopharmaceutical company. It designs, discovers, develops, and commercializes ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.